The relationship between subtle cognitive decline and Alzheimer's disease (AD) pathology as measured by biomarkers in settings outside of specialty memory clinics is not well characterized.
Objective
To investigate how subtle longitudinal cognitive decline relates to neuroimaging biomarkers in individuals drawn from a population-based study in an economically depressed, small-town area in southwestern Pennsylvania, USA.
Methods
A subset of participants without dementia (N = 115, age 76.53 years ± 6.25) from the Monongahela Youghiogheny Healthy Aging Team (MYHAT) study completed neuroimaging including magnetic resonance imaging (MRI) measures of AD-signature region cortical thickness and white matter hyperintensities (WMH), Pittsburgh compound B (PiB)-positron emission tomography (PET) for amyloid-β (Aβ) deposition, and [18F]AV-1451-PET for tau deposition. Neuropsychological evaluations were completed at multiple timepoints up to 11 years prior to neuroimaging. Aβ positivity was determined using a regional approach. We used linear mixed models to examine neuroimaging biomarker associations with retrospective cognitive slopes in five domains and a global cognitive composite.
Results
Among Aβ(+) participants (38%), there were associations between (i) tau Braak III/IV and language decline (p < 0.05), (ii) cortical thickness and both memory decline (p < 0.001) and global cognitive decline (p < 0.01), and (iii) WMH and decline in executive function (p < 0.05) and global cognition (p < 0.05). Among Aβ(-) participants, there was an association between tau Braak III/IV and decline on tests of attention/psychomotor speed (p < 0.05).
Conclusions
These findings confirm an Aβ-dependent early AD biomarker pathway, and suggest a possible Aβ-independent, non-AD process underlying subtle cognitive decline in a population-based sample of older adults without dementia.
World Health Organization. Global action plan on the public health response to dementia 2017-2025. Geneva: World Health Organization, 2017.
2.
JackCRJr.AndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
3.
WeigandAJBangenKJThomasKR, et al.Is tau in the absence of amyloid on the Alzheimer's continuum?: a study of discordant PET positivity. Brain Commun2020; 2: fcz046.
4.
BakerJELimYYPietrzakRH, et al.Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement (Amst)2017; 6: 108–121.
5.
InselPSWeinerMMackinRS, et al.Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology2019; 93: e322–e333.
6.
MaassALockhartSNHarrisonTM, et al.Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci2018; 38: 530–543.
7.
BilgelMAnYHelphreyJ, et al.Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain2018; 141: 2475–2485.
8.
ChenYDennyKGHarveyD, et al.Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based elderly cohort. Alzheimers Dement2017; 13: 399–405.
9.
CranePKGibbonsLEMcCurrySM, et al.Importance of home study visit capacity in dementia studies. Alzheimers Dement2016; 12: 419–426.
10.
MitchellAJShiri-FeshkiM. Rate of progression of mild cognitive impairment to dementia–meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand2009; 119: 252–265.
11.
SnitzBEWangTCloonanYK, et al.Risk of progression from subjective cognitive decline to mild cognitive impairment: the role of study setting. Alzheimers Dement2018; 14: 734–742.
12.
TurneyICLaoPJRenteriaMA, et al.Brain aging among racially and ethnically diverse middle-aged and older adults. JAMA Neurol2023; 80: 73–81.
13.
Gilmore-BykovskyiACroffRGloverCM, et al.Traversing the aging research and health equity divide: toward intersectional frameworks of research justice and participation. Gerontologist2022; 62: 711–720.
14.
Gilmore-BykovskyiALJinYGleasonC, et al.Recruitment and retention of underrepresented populations in Alzheimer's disease research: a systematic review. Alzheimers Dement (N Y)2019; 5: 751–770.
15.
GodboleNKwonSCBeasleyJM, et al.Assessing equitable inclusion of underrepresented older adults in Alzheimer's disease, related cognitive disorders, and aging-related research: a scoping review. Gerontologist2023; 63: 1067–1077.
16.
RamanRQuirozYTLangfordO, et al.Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial. JAMA Netw Open2021; 4: e2114364.
17.
KambohMIFanKHYanQ, et al.Population-based genome-wide association study of cognitive decline in older adults free of dementia: identification of a novel locus for the attention domain. Neurobiol Aging2019; 84: 239 e215–239 e224.
18.
MorrisJC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993; 43: 2412–2414.
19.
GanguliMBiltJVLeeCW, et al.Cognitive test performance predicts change in functional status at the population level: the MYHAT Project. J Int Neuropsychol Soc2010; 16: 761–770.
20.
GanguliMFuBSnitzBE, et al.Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort. Neurology2013; 80: 2112–2120.
21.
FischlB. Freesurfer. Neuroimage2012; 62: 774–781.
22.
TziortziACSearleGETzimopoulouS, et al.Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage2011; 54: 264–277.
23.
TudorascuDLMinhasDSLaoPJ, et al.The use of Centiloids for applying [(11)C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimers Dement (Amst)2018; 10: 332–339.
24.
JackCRJr.WisteHJWeigandSD, et al.Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement2017; 13: 205–216.
25.
WuMFatukasiOYangS, et al.HIV Disease and diabetes interact to affect brain white matter hyperintensities and cognition. AIDS2018; 32: 1803–1810.
26.
WuMRosanoCButtersM, et al.A fully automated method for quantifying and localizing white matter hyperintensities on MR images. Psychiatry Res2006; 148: 133–142.
27.
SnitzBETudorascuDLYuZ, et al.Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non-demented older adults. Alzheimers Dement (Amst)2020; 12: e12018.
28.
BakerSLMaassAJagustWJ. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief2017; 15: 648–657.
29.
MaassALandauSBakerSL, et al.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage2017; 157: 448–463.
30.
SchollMLockhartSNSchonhautDR, et al.PET Imaging of tau deposition in the aging human brain. Neuron2016; 89: 971–982.
31.
CohenADMowreyWWeissfeldLA, et al.Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage2013; 71: 207–215.
32.
GanguliMSnitzBVander BiltJ, et al.How much do depressive symptoms affect cognition at the population level? The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) study. Int J Geriatr Psychiatry2009; 24: 1277–1284.
33.
VandenbrouckeJPvon ElmEAltmanDG, et al.Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med2007; 147: W163–W194.
34.
JackCRJr.WisteHJWeigandSD, et al.Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol2014; 13: 997–1005.
35.
JansenWJJanssenOTijmsBM, et al.Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol2022; 79: 228–243.
36.
GovindpaniKMcNamaraLGSmithNR, et al.Vascular dysfunction in Alzheimer's disease: a prelude to the pathological process or a consequence of it?J Clin Med2019; 8: 651.
37.
DickersonBCEichenbaumH. The episodic memory system: neurocircuitry and disorders. Neuropsychopharmacology2010; 35: 86–104.
38.
NelsonPTAlafuzoffIBigioEH, et al.Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol2012; 71: 362–381.
39.
BetthauserTJKoscikRLJonaitisEM, et al.Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain2020; 143: 320–335.
40.
GagliardiGRodriguez-VieitezEMontalV, et al.Cortical microstructural changes predict tau accumulation and episodic memory decline in older adults harboring amyloid. Commun Med (Lond)2023; 3: 106.
41.
AliHFFastLKhalilA, et al.White matter hyperintensities are an independent predictor of cognitive decline 3 years following first-ever stroke-results from the PROSCIS-B study. J Neurol2023; 270: 1637–1646.
42.
DupontPSBoctiCJoannetteM, et al.Amyloid burden and white matter hyperintensities mediate age-related cognitive differences. Neurobiol Aging2020; 86: 16–26.
43.
RoseboroughARamirezJBlackSE, et al.Associations between amyloid beta and white matter hyperintensities: a systematic review. Alzheimers Dement2017; 13: 1154–1167.
44.
BackmanLJonesSBergerAK, et al.Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology2005; 19: 520–531.
45.
BellevilleSFouquetCHudonC, et al.Neuropsychological measures that predict progression from mild cognitive impairment to Alzheimer's type dementia in older adults: a systematic review and meta-analysis. Neuropsychol Rev2017; 27: 328–353.
46.
WeintraubSWicklundAHSalmonDP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med2012; 2: a006171.
47.
TianRZhangYLiuF, et al.A neuropsychological profile and its correlation with neuroimaging markers in patients with subcortical ischaemic vascular dementia. Int J Geriatr Psychiatry2023; 38: e5900.
48.
TraykovLBaudicSThibaudetMC, et al.Neuropsychological deficit in early subcortical vascular dementia: comparison to Alzheimer's disease. Dement Geriatr Cogn Disord2002; 14: 26–32.
49.
CraryJFTrojanowskiJQSchneiderJA, et al.Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol2014; 128: 755–766.
50.
BesserLMMockCTeylanMA, et al.Differences in cognitive impairment in primary age-related tauopathy versus Alzheimer disease. J Neuropathol Exp Neurol2019; 78: 219–228.
51.
WalkerJMGonzalesMMGoetteW, et al.Cognitive and neuropsychological profiles in Alzheimer's disease and primary age-related tauopathy and the influence of comorbid neuropathologies. J Alzheimers Dis2023; 92: 1037–1049.
52.
FarrellMEPappKVBuckleyRF, et al.Association of emerging beta-amyloid and tau pathology with early cognitive changes in clinically normal older adults. Neurology2022; 98: e1512–e1524.
53.
SperlingRAMorminoECSchultzAP, et al.The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol2019; 85: 181–193.
54.
AschenbrennerAJGordonBABenzingerTLS, et al.Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology2018; 91: e859–e866.
55.
HohmanTJTommetDMarksS, et al.Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline. Neurobiol Aging2017; 58: 120–128.
56.
BoylePAWangTYuL, et al.To what degree is late life cognitive decline driven by age-related neuropathologies?Brain2021; 144: 2166–2175.
57.
DodgeHHZhuJHughesTF, et al.Cohort effects in verbal memory function and practice effects: a population-based study. Int Psychogeriatr2017; 29: 137–148.
58.
GanguliMFuBSnitzBE, et al.Vascular risk factors and cognitive decline in a population sample. Alzheimer Dis Assoc Disord2014; 28: 9–15.
59.
GanguliMLeeCWSnitzBE, et al.Rates and risk factors for progression to incident dementia vary by age in a population cohort. Neurology2015; 84: 72–80.
60.
Rodriguez-GomezOAbdelnourCJessenF, et al.Influence of sampling and recruitment methods in studies of subjective cognitive decline. J Alzheimers Dis2015; 48: S99–S107.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
